71 related articles for article (PubMed ID: 23747836)
1. Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer.
Tergas AI; Havrilesky LJ; Fader AN; Guntupalli SR; Huh WK; Massad LS; Rimel BJ
Gynecol Oncol; 2013 Sep; 130(3):421-5. PubMed ID: 23747836
[TBL] [Abstract][Full Text] [Related]
2. Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales.
Martin-Hirsch P; Rash B; Martin A; Standaert B
BJOG; 2007 Apr; 114(4):408-15. PubMed ID: 17378815
[TBL] [Abstract][Full Text] [Related]
3. The value of repeat Pap smear at the time of initial colposcopy.
Spitzer M; Ryskin M; Chernys AE; Shifrin A
Gynecol Oncol; 1997 Oct; 67(1):3-7. PubMed ID: 9345348
[TBL] [Abstract][Full Text] [Related]
4. The value of cervical cytology in HIV-infected women.
Del Priore G; Maag T; Bhattacharya M; Garcia PM; Till M; Lurain JR
Gynecol Oncol; 1995 Mar; 56(3):395-8. PubMed ID: 7705674
[TBL] [Abstract][Full Text] [Related]
5. A decision analysis of practice patterns used in evaluating and treating abnormal Pap smears.
Roland PY; Naumann RW; Alvarez RD; Kilgore LC; Partridge EE
Gynecol Oncol; 1995 Oct; 59(1):75-80. PubMed ID: 7557619
[TBL] [Abstract][Full Text] [Related]
6. Is cytologic screening an effective surveillance method for detection of vaginal recurrence of uterine cancer?
Cooper AL; Dornfeld-Finke JM; Banks HW; Davey DD; Modesitt SC
Obstet Gynecol; 2006 Jan; 107(1):71-6. PubMed ID: 16394042
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance.
Bristow RE; Purinton SC; Santillan A; Diaz-Montes TP; Gardner GJ; Giuntoli RL
Gynecol Oncol; 2006 Nov; 103(2):709-13. PubMed ID: 16797686
[TBL] [Abstract][Full Text] [Related]
8. A study of Pap test history and histologically determined cervical cancer in NSW women, 1997-2003.
Morrell S; Taylor R; Wain G
J Med Screen; 2005; 12(4):190-6. PubMed ID: 16417696
[TBL] [Abstract][Full Text] [Related]
9. Should endocervical curettage routinely be performed at the time of colposcopy? A cost-effectiveness analysis.
Shepherd JP; Guido R; Lowder JL
J Low Genit Tract Dis; 2014 Apr; 18(2):101-8. PubMed ID: 24270197
[TBL] [Abstract][Full Text] [Related]
10. Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence.
Orr JM; Barnett JC; Leath CA
Gynecol Oncol; 2011 Sep; 122(3):501-4. PubMed ID: 21714992
[TBL] [Abstract][Full Text] [Related]
11. Repeating cytology at initial colposcopy does not improve detection of high-grade abnormalities: a retrospective cohort study of 6595 women.
Rieck GC; Bhaumik J; Beer HR; Leeson SC
Gynecol Oncol; 2006 May; 101(2):228-33. PubMed ID: 16325241
[TBL] [Abstract][Full Text] [Related]
12. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
13. [Cervical cancer screening and associated treatment costs in France].
Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
[TBL] [Abstract][Full Text] [Related]
14. Comparison of visual inspection and Papanicolau (PAP) smears for cervical cancer screening in Honduras: should PAP smears be abandoned?
Perkins RB; Langrish SM; Stern LJ; Figueroa J; Simon CJ
Trop Med Int Health; 2007 Sep; 12(9):1018-25. PubMed ID: 17875013
[TBL] [Abstract][Full Text] [Related]
15. What is the least costly strategy to evaluate cervical abnormalities in rural women? Comparing telemedicine, local practitioners, and expert physicians.
Bishai DM; Ferris DG; Litaker MS
Med Decis Making; 2003; 23(6):463-70. PubMed ID: 14672106
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
17. High-resolution microendoscopy: a point-of-care diagnostic for cervical dysplasia in low-resource settings.
Grant BD; Fregnani JH; Possati Resende JC; Scapulatempo-Neto C; Matsushita GM; Mauad EC; Quang T; Stoler MH; Castle PE; Schmeler KM; Richards-Kortum RR
Eur J Cancer Prev; 2017 Jan; 26(1):63-70. PubMed ID: 26637074
[TBL] [Abstract][Full Text] [Related]
18. Decision analysis for best management of mildly dyskaryotic smear.
Johnson N; Sutton J; Thornton JG; Lilford RJ; Johnson VA; Peel KR
Lancet; 1993 Jul; 342(8863):91-6. PubMed ID: 8100917
[TBL] [Abstract][Full Text] [Related]
19. Biospectroscopy insights into the multi-stage process of cervical cancer development: probing for spectral biomarkers in cytology to distinguish grades.
Purandare NC; Patel II; Trevisan J; Bolger N; Kelehan R; von Bünau G; Martin-Hirsch PL; Prendiville WJ; Martin FL
Analyst; 2013 Jul; 138(14):3909-16. PubMed ID: 23338619
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer.
Armstrong A; Otvos B; Singh S; Debernardo R
Gynecol Oncol; 2013 Dec; 131(3):503-7. PubMed ID: 24060416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
